Galioto G B, Passali D, Catalano G B, Mevio E, Lepore A M, Romoli L
Otorhinolaryngologic Department, Policlinico S. Matteo, University of Pavia, Italy.
Int J Clin Pharmacol Ther. 1995 Apr;33(4):204-7.
In this study efficacy and tolerability of flurithromycin ethylsuccinate (FE) were evaluated in ear, nose and throat infections. One hundred and three patients were treated with FE tablets 375 mg 12-hourly for a mean duration of treatment of 8.2 days and they were divided into groups according to the pathology: pharyngitis/tonsillitis (chronic 7, acute 38), rhinosinusitis (chronic 7, acute 12), otitis (chronic 6, acute 32) and sialadenitis (acute 1). Patients evaluable for clinical efficacy were 101, among them a complete recovery was registered in 88.2%, an improvement in 9.9% and a treatment failure in 1.9%. Bacteriological evaluation was possible in 95 patients, showing the eradication of the pathogen in 94.7%. Tolerability was judged to be excellent in 81.6%, good in 15.5% and discrete in 2.9%. These results demonstrate that FE is safe and effective in the treatment of infections established on acute or chronic inflammatory states.
在本研究中,对琥乙红霉素(FE)治疗耳、鼻和咽喉感染的疗效及耐受性进行了评估。103例患者接受375mg FE片剂治疗,每12小时一次,平均治疗时长为8.2天,根据病理情况分为以下几组:咽炎/扁桃体炎(慢性7例,急性38例)、鼻窦炎(慢性7例,急性12例)、中耳炎(慢性6例,急性32例)和涎腺炎(急性1例)。可评估临床疗效的患者有101例,其中88.2%实现完全康复,9.9%病情改善,1.9%治疗失败。95例患者可进行细菌学评估,结果显示94.7%的患者病原体被根除。耐受性评估结果为:81.6%为优,15.5%为良,2.9%为差。这些结果表明,FE治疗急性或慢性炎症状态下的感染安全有效。